Opthea IPO: What Investors Should Know About The Genentech, Regeneron Challenger

Opthea, an Australian clinical-stage biotech company, is going public to help fund its Phase 3 trials and take on two large biotech companies.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.